Article
Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission.
Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973, USA.
Neuropsychopharmacology (impact factor:
7.99).
12/2001;
25(5):704-12.
DOI:10.1016/S0893-133X(01)00268-8
pp.704-12
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
[show abstract] [hide abstract]
ABSTRACT: It has been postulated that disturbances in glutamatergic transmission may contribute to the pathophysiology of schizophrenia. This view is based on several findings: (1) the noncompetitive NMDA receptor antagonists, phencyclidine and ketamine, induce both positive and negative psychotic symptoms in humans, which closely resemble those observed in schizophrenia; (2) a number of animal studies have shown that neuroleptics that ameliorate symptoms of schizophrenia (e.g. clozapine) also inhibit the effects of NMDA antagonists; (3) postmortem and in vivo studies have revealed alterations in ionotropic glutamate receptors (NMDA, AMPA, KA) and their modulatory sites in schizophrenia; (4) compounds enhancing the function of NMDA receptors potentiate the antipsychotic effects of neuroleptics in schizophrenic patients.Polish journal of pharmacology 55(2):133-54.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
51% inhibition
68% inhibition
82% inhibition
acute pretreatment
cortical NMDA-antagonist induced increases
DA response
endogenous GABA
GABA catabolizing enzyme GABA-AT
inhibition
inhibitory capacity
mesocorticolimbic DA transmission
midbrain DA neurons
NAcc PCP-induced DA activity
NMDA antagonist induced dopamine
PCP)-induced DA release
PCP-induced DA release
PFC
Preferential increases
Subchronic treatment
subcortical areas